NCT06250465 AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry
| NCT ID | NCT06250465 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Condition | Chronic Lymphocytic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-03-24 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-03-24 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
For until very recently CLL has been considered an uncurable disease, with the only few exceptions of a part of patients capable of undergoing and successfully standing allogeneic stem cell transplant. However, the introduction of chemoimmunotherapy in particular the FCR (fludarabine, cyclophosphamide, rituximab) regimen has established a relevant population of IgVH mutated patients, who remain relapse-free for up to 10 years with a clear plateau at this level. However, for the largest proportion of all CLL patients the disease is still associated with a reduction in life expectancy as compared to a matched population. The field has made further substantial progress by the introduction of BTK inhibitors and Bcl2 inhibitors, novel antibodies as well as by the understanding of the role of minimal residual disease (MRD), mutations and their clonal evolution over time as risk factors and factors governing the kind and duration of therapy. Due to the limited follow up of frontline therapy trials using novel drugs, it is not yet clear, what the long-term results with many of the new drugs will be. Particularly, long-term PFS, the potential for cure and the long-term safety issues remain relevant parameters requiring examination, as are infections, interactions with other drugs or quality of life issues. CLL has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of this disease.
Eligibility Criteria
Inclusion Criteria: * The registry will include patients ≥ 18 years with CLL. Exclusion Criteria: * There are no specific exclusion criteria.
Contact & Investigator
Richard Greil, MD
PRINCIPAL INVESTIGATOR
Department of internal Medicine III, Paracelsus Medical University Salzburg, Austria
Frequently Asked Questions
Who can join the NCT06250465 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06250465 currently recruiting?
Yes, NCT06250465 is actively recruiting participants. Contact the research team at office@agmt.at for enrollment information.
Where is the NCT06250465 trial being conducted?
This trial is being conducted at Feldkirch, Austria, Innsbruck, Austria, Kufstein, Austria, Linz, Austria and 5 additional locations.
Who is sponsoring the NCT06250465 clinical trial?
NCT06250465 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. The principal investigator is Richard Greil, MD at Department of internal Medicine III, Paracelsus Medical University Salzburg, Austria. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.